Reviva Pharma up on patient enrollment updates in late-stage study

Reviva Pharmaceuticals Holdings

31/10/2022 15:07

** Shares of drug developer Reviva Pharmaceuticals Holdings
Inc  RVPH.O  rise 14.12% to $4.34 
    ** Co says it is has completed over 30% enrollment in the
U.S. for a pivotal late-stage study evaluating its lead clinical
candidate "brilaroxazine"  urn:newsml:reuters.com:*:nGNXKlkjs
    ** The study is testing RVPH's antipsychotic agent
"brilaroxazine" in nearly 400 patients with acute schizophrenia
compared to placebo 
    ** Schizophrenia is a chronic, severe mental disorder;
psychotic symptoms include hallucinations and unusual thinking
while negative symptoms include disinterest in daily activities
and social withdrawal
    ** Reviva initiated its first clinical site at the end of
Jan in the U.S.; recently initiated multiple sites in Europe and
expects enrollment at multiple sites in India in the year - RVPH
    ** Co expects to post top-line data from the study in
mid-2023
    ** Including session's gain, stock up ~50% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))